Gamble Tyler C, Sellers Holly S
Pilgrim's Corporation, Greeley, CO 80634, USA,
Poultry Diagnostic and Research Center, College of Veterinary Medicine, The University of Georgia, Athens, Georgia 30602, USA.
Avian Dis. 2022 Dec;66(4):427-431. doi: 10.1637/aviandiseases-D-22-99991.
Prevention of tenosynovitis/viral arthritis caused by variant avian reoviruses within commercial broiler production has become increasingly more challenging because of the lack of protection afforded by the current commercially available vaccines. Avian reoviruses isolated from clinical cases of tenosynovitis/viral arthritis in recent years are antigenically distinct from nearly all of the commercially licensed modified live and inactivated biologics available in the United States. The emergence of new variants is likely shaped by a lack of homologous protection coupled with selection pressure influences and results in antigenically diverse populations of avian reoviruses. One tool available to the poultry industry is the use of autogenous (custom) vaccines. Although these can be effective, isolation, characterization, and screening of isolates from clinical cases is paramount for the selection of isolates to include in these vaccines. With no treatment options, control can only be attained via prevention of infection. To achieve this goal, commercially licensed products with antigenic applicability and broadly cross-protective vaccine strains are needed.
由于目前市售疫苗缺乏保护作用，在商业肉鸡生产中预防由变异禽呼肠孤病毒引起的腱鞘炎/病毒性关节炎变得越来越具有挑战性。近年来从腱鞘炎/病毒性关节炎临床病例中分离出的禽呼肠孤病毒在抗原性上与美国几乎所有商业许可的改良活疫苗和灭活生物制品都不同。新变种的出现可能是由于缺乏同源保护以及选择压力的影响，导致禽呼肠孤病毒出现抗原性多样的群体。家禽业可用的一种工具是使用自体（定制）疫苗。虽然这些疫苗可能有效，但从临床病例中分离、鉴定和筛选分离株对于选择纳入这些疫苗的分离株至关重要。由于没有治疗选择，只能通过预防感染来实现控制。为实现这一目标，需要具有抗原适用性和广泛交叉保护疫苗株的商业许可产品。
